OBJECTIVE: To determine whether proinflammatory cytokine treatment or the complete absence of select cytokines modulates the expression of RANKL and osteoprotegerin (OPG) in synovial fibroblasts. METHODS: Fibroblasts were isolated from normal and rheumatoid human synovium and from normal or arthritic joints of wild-type and cytokine gene-deficient (interleukin-4-knockout [IL-4 (-/-)] and interferon-gamma-knockout [IFNgamma (-/-)]) mice. Fibroblasts were stimulated with proinflammatory cytokines (tumor necrosis factor alpha [TNFalpha], IL-1beta, and IL-17) or antiosteoclastogenic cytokines (IL-4 and IFNgamma), alone or in combination, and the expression of RANKL and OPG was measured. RESULTS: Proinflammatory cytokine-stimulated fibroblasts from rheumatoid and arthritic mouse joints expressed higher levels of RANKL and OPG than those from normal joints. IL-4 suppressed RANKL expression and increased OPG expression, IFNgamma reduced the production of both RANKL and OPG, and IL-17 had only a modest effect on the expression of RANKL or OPG. Additive effects of combination treatment (TNFalpha/IL-17 or IL-1beta/IL-17) were observed only in the human system. Extensive destruction was observed in the arthritic joints of IL-4 (-/-) mice, with a corresponding upward shift of the RANKL:OPG ratios. However, an IL-17 deficiency did not attenuate arthritis or reduce bone resorption. CONCLUSION: Proinflammatory cytokines induce the expression of RANKL and OPG in both human and murine synovial fibroblasts. The RANKL:OPG ratios are shifted in favor of bone protection by IL-4 treatment, and, to a lesser extent, by IFNgamma treatment. Unexpectedly, an IL-17 deficiency alone does not induce reduced inflammatory bone destruction. Our results suggest that synovial fibroblasts may significantly contribute to bone resorption through modulation of RANKL and OPG production in a cytokine-rich milieu of inflamed joints.
OBJECTIVE: To determine whether proinflammatory cytokine treatment or the complete absence of select cytokines modulates the expression of RANKL and osteoprotegerin (OPG) in synovial fibroblasts. METHODS: Fibroblasts were isolated from normal and rheumatoidhuman synovium and from normal or arthritic joints of wild-type and cytokine gene-deficient (interleukin-4-knockout [IL-4 (-/-)] and interferon-gamma-knockout [IFNgamma (-/-)]) mice. Fibroblasts were stimulated with proinflammatory cytokines (tumor necrosis factor alpha [TNFalpha], IL-1beta, and IL-17) or antiosteoclastogenic cytokines (IL-4 and IFNgamma), alone or in combination, and the expression of RANKL and OPG was measured. RESULTS: Proinflammatory cytokine-stimulated fibroblasts from rheumatoid and arthritic mouse joints expressed higher levels of RANKL and OPG than those from normal joints. IL-4 suppressed RANKL expression and increased OPG expression, IFNgamma reduced the production of both RANKL and OPG, and IL-17 had only a modest effect on the expression of RANKL or OPG. Additive effects of combination treatment (TNFalpha/IL-17 or IL-1beta/IL-17) were observed only in the human system. Extensive destruction was observed in the arthritic joints of IL-4 (-/-) mice, with a corresponding upward shift of the RANKL:OPG ratios. However, an IL-17 deficiency did not attenuate arthritis or reduce bone resorption. CONCLUSION: Proinflammatory cytokines induce the expression of RANKL and OPG in both human and murine synovial fibroblasts. The RANKL:OPG ratios are shifted in favor of bone protection by IL-4 treatment, and, to a lesser extent, by IFNgamma treatment. Unexpectedly, an IL-17 deficiency alone does not induce reduced inflammatory bone destruction. Our results suggest that synovial fibroblasts may significantly contribute to bone resorption through modulation of RANKL and OPG production in a cytokine-rich milieu of inflamed joints.
Authors: Wenfeng Tan; Hui Wu; Jian Zhao; Lezlie A Derber; David M Lee; Nancy A Shadick; Doyt L Conn; Edwin A Smith; Vivian H Gersuk; Gerald T Nepom; Larry W Moreland; Daniel E Furst; Susan D Thompson; Beth L Jonas; V Michael Holers; David N Glass; Pojen P Chen; S Louis Bridges; Michael E Weinblatt; Harold E Paulus; Betty P Tsao Journal: Arthritis Rheum Date: 2010-10
Authors: Keith M Hamel; Yanxia Cao; Susan Ashaye; Yumei Wang; Robert Dunn; Marilyn R Kehry; Tibor T Glant; Alison Finnegan Journal: J Immunol Date: 2011-09-23 Impact factor: 5.422
Authors: Paul D Doodes; Yanxia Cao; Keith M Hamel; Yumei Wang; Rachel L Rodeghero; Katalin Mikecz; Tibor T Glant; Yoichiro Iwakura; Alison Finnegan Journal: J Immunol Date: 2009-12-18 Impact factor: 5.422
Authors: Balint Farkas; Ferenc Boldizsar; Oktavia Tarjanyi; Anna Laszlo; Simon M Lin; Gabor Hutas; Beata Tryniszewska; Aaron Mangold; Gyorgy Nagyeri; Holly L Rosenzweig; Alison Finnegan; Katalin Mikecz; Tibor T Glant Journal: Arthritis Res Ther Date: 2009-02-16 Impact factor: 5.156
Authors: Sujata Sarkar; Laura A Cooney; Peter White; Deborah B Dunlop; Judith Endres; Julie M Jorns; Matthew J Wasco; David A Fox Journal: Arthritis Res Ther Date: 2009-10-26 Impact factor: 5.156